オプションチェーンは、AngioDynamicsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、AngioDynamicsの市場センチメントを評価します。.

AngioDynamics (NASDAQ:ANGO) 株価情報, オプションチェーン

AngioDynamics

AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.

AngioDynamics Inc

ANGO WORLD HOLDINGS INC by ANGO World Holdings, Inc.

Angold Resources Ltd Ordinary Shares

News

ANGO

AngioDynamics Says It Initiated AMBITION BTK RCT And Registry To Advance Treatment For Critical Limb Ischemia

Peer-reviewed data highlights successful clinical study with 35.5% clot burden reduction, validating the safety, efficacy, and efficiency of AlphaVac F1885 System in pulmonary embolism treatment.
AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the publication of the results from the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV) in the Journal of the Society for Cardiovascular Angiography &amp; Interventions (JSCAI). The article, "Novel Mechanical Aspiration Thrombectomy in Patients with Acute Pulmonary Embolism: Results from the Prospective APEX-AV Trial," was published December 27, 2024.
Pulmonary embolism (PE), a potentially life-threatening condition, affects approximately 900,000 individuals annually in the United States, with 10-30% of cases resulting in death within one month of diagnosis, according to the American Lung Association.1
The primary efficacy endpoint of the APEX-AV trial was the reduction in RV/LV ratio between baseline and 48 hours post-procedure. The primary safety endpoint was the rate of MAEs, including events such as major bleeding and serious device-related clinical deterioration, pulmonary vascular injury, and cardiac injury within the first 48 hours. Patients were followed for 30 days post-index procedure. The results demonstrated the device as a safe and effective treatment for acute intermediate-risk PE with a significant reduction in RV/LV ratio and clot burden with a low rate of adverse events.
The APEX-AV trial demonstrated a 35.5% reduction in clot burden (via the Modified Miller index score), comparing favorably to other mechanical aspiration devices on the market.2 The unique design features of the device, including its funnel tip, optional wireless navigation, and blood loss mitigation, contributed to clinically significant improvements in both safety and efficacy.

Biotech

General

AngioDynamics Announces 35.5% Clot Reduction With AlphaVac F1885 System in Trial, Meeting Primary Endpoints In Pulmonary Embolism Treatment Published In The Journal Of The Society For Cardiovascular Angiography & Interventions Titled "Novel Mechanical Aspiration Thrombectomy In Patients With Acute Pulmonary Embolism: Results From The Prospective APEX-AV Trial"

HC Wainwright &amp; Co. analyst Yi Chen maintains AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) with a Buy and raises the price target from $14 to $15.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $15

U.S. stocks traded slightly lower midway through trading, with the Dow Jones index falling around 0.1% on Wednesday.
The Dow traded down 0.05% to 42,507.21 while the NASDAQ dipped 0.14% to 19,461.93. The S&amp;P 500 also fell, dropping, 0.03% to 5,907.51.
Check This Out: <a href="https://www.benzinga.com/25/01/42839544/wells-fargo-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Wells Fargo Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Materials shares rose by 0.1% on Wednesday.
In trading on Wednesday, utilities shares tumbled by 1%.
Top Headline
U.S. initial jobless claims fell by 10,000 to 201,000 in the week ending Jan. 4, recording the lowest level in eleven months and versus market estimates of 218,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Sana Biotechnology, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) shares shot up 193% to $4.8390 after the company on Tuesday announced clinical trial results from its type 1 diabetes study of islet cell transplantation without immunosuppression.</li>
<li>Shares of Silo Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>)got a boost, surging 141% to $2.6680 after the company announced it was awarded a US patent for its PTSD treatment titled &#8216;Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.&#8217;</li>
<li>AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) shares were also up, gaining 29% to $12.11 after the company reported better-than-expected second-quarter financial results and raised its FY25 adjusted EPS guidance.</li>
</ul>
Equities Trading DOWN
<ul>
<li>DatChat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DATS#NASDAQ">DATS</a>) shares dropped 65% to $3.13 after the company announced the pricing of a $5.1 million registered direct offering priced at-the-market under Nasdaq rules.</li>
<li>Shares of Jasper Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) were down 59% to $7.26. The company reported preliminary data from its BEACON Phase 1b/2a study.</li>
<li>XTI Aerospace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) was down, falling 54% to $0.0529. XTI Aerospace priced $20 million offering of 363,636,364 shares of common stock at a price of $0.055 per share.</li>
</ul>
Commodities In commodity news, oil traded down 1% to $73.50 while gold traded up 0.4% at $2,676.80.
Silver traded up 0.5% to $30.850 on Wednesday, while copper rose 1.2% to $4.2475.
Euro zone
European shares were lower today. The eurozone's STOXX 600 declined 0.54%, Germany's DAX 40 fell 0.34% and France's CAC 40 dipped 1.1%. Spain's IBEX 35 Index fell 0.61%, while London's FTSE 100 slipped 0.24%.
Asia Pacific Markets
Asian markets closed mostly lower on Wednesday, with Japan's Nikkei 225 falling 0.26%, China's Shanghai Composite Index gaining 0.02%, Hong Kong's Hang Seng Index declining 0.86% and India's BSE Sensex falling 0.07%.
Economics
<ul>
<li>U.S. private businesses added 122,000 workers to their payrolls in December down from 146,000 in November and versus expectations of 140,000.</li>
<li>U.S. initial jobless claims fell by 10,000 to 201,000 in the week ending Jan. 4, recording the lowest level in eleven months and versus market estimates of 218,000.</li>
<li>The Energy Information Administration said U.S. crude inventories declined by 0.959 million barrels last week, compared to market estimates of a 0.6 million barrel decline</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/42873668/jim-cramer-lemonade-is-up-too-much-this-health-care-stock-can-go-lower">Jim Cramer: Lemonade Is &#8216;Up Too Much,&#8217; This Health Care Stock Can Go Lower</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

DATS

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

SANA

SILO

XTIA

Crude Oil Down 1%; US Weekly Jobless Claims Decline

U.S. stocks were lower, with the Dow Jones index falling over 150 points on Wednesday.
Shares of AAR Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) rose sharply during Tuesday's session after posted stronger-than-expected <a href="https://www.benzinga.com/news/earnings/25/01/42862022/aar-shares-climb-on-better-than-expected-q2-results-details">second-quarter results.</a>
The company reported quarterly earnings of 90 cents per share, which beat the analyst consensus estimate of 84 cents. Quarterly revenue came in at $686.1 million, which beat the analyst consensus estimate of $654.18 million.
AAR shares jumped 9.6% to $67.67 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) shares jumped 249% to $5.77 after the company on Tuesday announced clinical trial results from its type 1 diabetes study of islet cell transplantation without immunosuppression.</li>
<li>Vir Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) gained 64% to $12.97 after the company announced it&#8217;s presenting initial Phase 1 data from its two dual-masked T-cell engagers (TCEs): VIR-5818 and VIR-5500.</li>
<li>AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) surged 25% to $11.74 after the company reported better-than-expected second-quarter financial results and raised its FY25 adjusted EPS guidance.</li>
<li>Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) rose 17% to $3.5900 after the company announced a strategic collaboration with AMD.</li>
<li>eBay Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) surged 11.5% to $70.44 after Meta announced a test in Germany, France and the US that will allow buyers to browse eBay listings directly on Facebook Marketplace.</li>
<li>Matthews International Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MATW#NASDAQ">MATW</a>) gained 10.2% to $29.87 as the company agreed to sell SGK Brand Solutions.</li>
<li>Arcadium Lithium plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NASDAQ">ALTM</a>) rose 8.6% to $5.72 after the company announced it secured CFIUS clearance regarding Rio Tinto&#8217;s proposed acquisition.</li>
<li>Cal-Maine Foods, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALM#NASDAQ">CALM</a>) gained 7.1% to $111.00 as the company posted better-than-expected results for its second quarter. The company said it set a quarterly record for total dozens sold and specialty dozens sold. It also announced a cash dividend of approximately $1.49 per share.</li>
<li>ADTRAN Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTN#NASDAQ">ADTN</a>) rose 6.3% to $10.25.</li>
<li>Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) gained 4.6% to $96.24 after the company announced it entered into a definitive deal to acquire Bold Medical.</li>
<li>UniFirst Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) gained 3.7% to $212.25 following upbeat quarterly earnings.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/42873668/jim-cramer-lemonade-is-up-too-much-this-health-care-stock-can-go-lower">Jim Cramer: Lemonade Is &#8216;Up Too Much,&#8217; This Health Care Stock Can Go Lower</a></li>
</ul>

Movers

ABSI

ADTN

ALTM

CALM

EBAY

MATW

AAR Posts Upbeat Results, Joins AngioDynamics, eBay, Cal-Maine Foods And Other Big Stocks Moving Higher On Wednesday

WIIM

AngioDynamics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 adjusted EPS guidance.

Guidance

Health Care

AngioDynamics Expects 2025 Adjusted EPS Loss Of $0.34 to $0.38 Compared To Prior Guidance Of $0.38-$0.42 And Consensus Of $0.40

<ul>
<li>The Company now expects Med Tech net sales to grow in the range of 12% to 15%, an increase from 10% to 12%</li>
<li>The Company now expects Med Device net sales to be flat, a decrease from 1% to 3%</li>
<li>The Company continues to expect Gross margin to be approximately 52% to 53%</li>
<li>The Company now expects Adjusted EBITDA in the range of $1.0 to $3.0 million, an increase from the previous guidance of a loss of $2.5 million to $0. The updated guidance compares to a pro forma Adjusted EBITDA loss of $3.2 million in fiscal 2024</li>
</ul>

AngioDynamics Continues To Expect 2025 Net Sales Of $282M-$288M, Representing Growth Of Between 4.2%–6.4% Over Fiscal 2024 Pro Forma Revenue Of $270.7M Versus Consensus Of $283.86M

AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.11) by 63.64 percent. The company reported quarterly sales of $73.02 million which beat the analyst consensus estimate of $70.93 million by 2.93 percent. This is a 9.17 percent increase over sales of $66.88 million the same period last year.

AngioDynamics Q2 2025 Adj EPS $(0.04) Beats $(0.11) Estimate, Sales $73.02M Beat $70.93M Estimate

<h3>Companies Reporting Before The Bell</h3>
• UniFirst (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) is estimated to report quarterly earnings at $2.21 per share on revenue of $606.60 million. 
• Simply Good Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMPL#NASDAQ">SMPL</a>) is projected to report quarterly earnings at $0.46 per share on revenue of $347.32 million. 
• Helen Of Troy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HELE#NASDAQ">HELE</a>) is likely to report quarterly earnings at $2.58 per share on revenue of $532.91 million. 
• MSC Industrial Direct Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) is likely to report quarterly earnings at $0.73 per share on revenue of $904.59 million. 
• Albertsons Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>) is estimated to report quarterly earnings at $0.66 per share on revenue of $18.82 billion. 
• Acuity Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AYI#NYSE">AYI</a>) is estimated to report quarterly earnings at $3.89 per share on revenue of $956.17 million. 
• AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) is expected to report quarterly loss at $0.11 per share on revenue of $70.93 million. 
<h3>Companies Reporting After The Bell</h3>
• Jefferies Financial Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JEF#NYSE">JEF</a>) is likely to report quarterly earnings at $1.04 per share on revenue of $1.83 billion. 
• Penguin Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENG#NASDAQ">PENG</a>) is expected to report quarterly earnings at $0.39 per share on revenue of $319.99 million. 
• Pricesmart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSMT#NASDAQ">PSMT</a>) is projected to report quarterly earnings at $1.29 per share on revenue of $1.24 billion. 
• Greenbrier Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBX#NYSE">GBX</a>) is projected to report quarterly earnings at $1.15 per share on revenue of $849.51 million. 
• Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) is estimated to report quarterly earnings at $0.22 per share on revenue of $70.15 million. 
• Saratoga Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAR#NYSE">SAR</a>) is projected to report quarterly earnings at $0.84 per share on revenue of $34.90 million. 
• Pure Cycle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCYO#NASDAQ">PCYO</a>) is likely to report earnings for its first quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HELE

PCYO

Penguin Solutions, Inc. - Ordinary Shares

PENG

PSMT

SMPL

Earnings Scheduled For January 8, 2025

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Tuesday.
Shares of Limoneira Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>) fell sharply in today's pre-market trading after reporting <a href="https://www.benzinga.com/quote/LMNR/news">fourth-quarter results.</a>
Limoneira posted an adjusted net loss of $1.6 million, or 9 cents per share, versus a year-ago loss of $2.6 million, or 15 cents per share. Its total net revenue rose to $43.9 million from $41.4 million in the year-ago quarter.
Limoneira shares fell 2.6% to $26.12 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Tutor Perini Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPC#NYSE">TPC</a>) dipped 12.1% to $22.01 in pre-market trading.</li>
<li>Astria Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>) fell 11.8% to $8.40 in pre-market trading.</li>
<li>Jiayin Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) shares fell 7.5% to $5.95 in pre-market trading. Jiayin Group, last week, announced the purchase of commercial property located in Shanghai, China for total cash consideration of RMB1.35 billion.</li>
<li>AngioDynamics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) dipped 7.3% to $8.21 in pre-market trading. AngioDynamics will report financial results for the second quarter of fiscal year before the opening bell on Wednesday, Jan. 8, 2025.</li>
<li>Phibro Animal Health Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) fell 5.2% to $20.51 in pre-market trading.</li>
<li>ADS-TEC Energy PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSE#NASDAQ">ADSE</a>) shares fell 3% to $13.70 in pre-market trading.</li>
<li>Vinci Partners Investments Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINP#NASDAQ">VINP</a>) fell 2.9% to $9.57 in pre-market trading.</li>
<li>Couchbase, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) declined 2.4% to $14.91 in pre-market trading.</li>
<li>Turtle Beach Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEAR#NASDAQ">HEAR</a>) declined 2.3% to $15.60 in pre-market trading.</li>
<li>Valhi, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) fell 2% to $21.30 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42648003/how-to-earn-500-a-month-from-qualcomm-stock-2">How To Earn $500 A Month From Qualcomm Stock</a></li>
</ul>

Pre-Market Outlook

ADSE

ATXS

BASE

HEAR

JFIN

LMNR

PAHC

VINP

Limoneira And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Across the recent three months, 4 analysts have shared their insights on AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $13.5, a high estimate of $14.00, and a low estimate of $12.00. This current average has decreased by 1.82% from the previous average price target of $13.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1733857211_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive AngioDynamics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to AngioDynamics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AngioDynamics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for AngioDynamics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into AngioDynamics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ANGO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AngioDynamics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About AngioDynamics</h2>
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
<h3>AngioDynamics: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: AngioDynamics's revenue growth over 3 months faced difficulties. As of 31 August, 2024, the company experienced a decline of approximately -14.22%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: AngioDynamics's net margin is impressive, surpassing industry averages. With a net margin of -18.96%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): AngioDynamics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -6.36% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): AngioDynamics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -4.19%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.02, AngioDynamics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 4 Analyst Recommendations For AngioDynamics

HC Wainwright &amp; Co. analyst Yi Chen reiterates AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) with a Buy and maintains $14 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on AngioDynamics, Maintains $14 Price Target

AngioDynamics shares are trading higher after the company announced the FDA has granted 510(k) clearance for its Nanoknife system for prostate tissue ablation.

The FDA Has Granted 510(k) Clearance For AngioDynamics' Nanoknife System For Prostate Tissue Ablation

AngioDynamics, University College London Hospital Launch International Multi-Center Study On Long Term Effects Of Treatment With NanoKnife System

A downtrend has been apparent in AngioDynamics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ango#NASDAQ">ANGO</a>) lately with too much selling pressure. The stock has declined 15.9% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company&#39;s ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.
<h2>How to Determine if a Stock is Oversold</h2>
We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.
RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.
Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock&#39;s price is reaching a point of reversal.
So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefitting from the inevitable rebound.
However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.
<h2>Why a Trend Reversal is Due for ANGO</h2>
The RSI reading of 24.7 for ANGO is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand.
<img alt="3-month RSI Chart for ANGO" class="chart" src="https://staticx-tuner.zacks.com/images/articles/charts/yseop/544/ANGO_RCI14.jpeg" style="height:auto; width:100%" title="" />
The RSI value is not the only factor that indicates a potential turnaround for the stock in the near term. On the fundamental side, there has been strong agreement among the sell-side analysts covering the stock in raising earnings estimates for the current year. Over the last 30 days, the consensus EPS estimate for ANGO has increased 0.8%. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.
Moreover, ANGO currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock&#39;s potential turnaround in the near term.
<a href="https://www.zacks.com/stock/news/2347418/angiodynamics-ango-loses-15-86-in-4-weeks-here-s-why-a-trend-reversal-may-be-around-the-corner?cid=CS-BENZ-FT-tale_of_the_tape|rsi-2347418">To read this article on Zacks.com click here.</a>

Technicals

Small Cap

Tech

AngioDynamics Loses -15.86% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Throughout the last three months, 4 analysts have evaluated AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $13.25, along with a high estimate of $14.00 and a low estimate of $12.00. A decline of 10.17% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2024/1728054129_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive AngioDynamics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to AngioDynamics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of AngioDynamics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of AngioDynamics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into AngioDynamics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ANGO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AngioDynamics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know AngioDynamics Better</h2>
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
<h3>Understanding the Numbers: AngioDynamics's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining AngioDynamics's financials over 3 months reveals challenges. As of 31 May, 2024, the company experienced a decline of approximately -22.06% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -18.95%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): AngioDynamics's ROE excels beyond industry benchmarks, reaching -6.34%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -4.19%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.02.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Assess AngioDynamics: What You Need To Know

Canaccord Genuity analyst William Plovanic maintains AngioDynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) with a Buy and lowers the price target from $13 to $12.

Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $12

Press Releases

AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results

AngioDynamics Announces American Medical Association's CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver

AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System

AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation

AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event

AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results

AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI

AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia

Comments

AngioDynamics

AngioDynamics (ANGO) オプション

AngioDynamics (NASDAQ:ANGO) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル